MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021

Rhea-AI Summary

MannKind Corporation (NASDAQ:MNKD) is set to release its 2020 fourth quarter and full year financial results on February 25, 2021, at 9:00 AM ET. The call, featuring CEO Michael Castagna and CFO Steven Binder, will discuss financials and corporate updates. Investors can participate via the company's website or by telephone, with a replay available for 14 days post-call. MannKind focuses on inhaled therapeutic products, commercializing Afrezza, the only FDA-approved inhaled insulin in the U.S., which is also available in Brazil through partner Biomm SA.

Positive

• Upcoming discussion on 2020 financial results could provide insights into company performance.
• Afrezza is the only inhaled ultra rapid-acting mealtime insulin available in the U.S., indicating a unique market position.

Negative

• None.

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on Thursday, February 25, 2021.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 7174315#. A replay will also be available on MannKind's website for 14 days.

About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Phone: (818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When will MannKind Corporation release its Q4 2020 financial results?

MannKind Corporation will release its Q4 2020 financial results on February 25, 2021.

What time is the MannKind Corporation earnings call scheduled for?

The earnings call for MannKind Corporation is scheduled for 9:00 AM ET on February 25, 2021.

Who will present at the MannKind Corporation earnings call?

CEO Michael Castagna and CFO Steven Binder will present during the MannKind Corporation earnings call.

Where can I listen to MannKind Corporation's earnings call?

You can listen to MannKind Corporation's earnings call live on their website under News & Events.

Is Afrezza available outside the United States?

Yes, Afrezza is also available by prescription in Brazil, through MannKind's partner Biomm SA.